301 related articles for article (PubMed ID: 28053288)
1. Clinicopathological significance of SMAD4 loss in pancreatic ductal adenocarcinomas: a systematic review and meta-analysis.
Wang JD; Jin K; Chen XY; Lv JQ; Ji KW
Oncotarget; 2017 Mar; 8(10):16704-16711. PubMed ID: 28053288
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological significance and prognostic role of chemokine receptor CXCR4 expression in pancreatic ductal adenocarcinoma, a meta-analysis and literature review.
Ding Y; Du Y
Int J Surg; 2019 May; 65():32-38. PubMed ID: 30902754
[TBL] [Abstract][Full Text] [Related]
4. SMAD4 loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells.
Chen YW; Hsiao PJ; Weng CC; Kuo KK; Kuo TL; Wu DC; Hung WC; Cheng KH
BMC Cancer; 2014 Mar; 14():181. PubMed ID: 24625091
[TBL] [Abstract][Full Text] [Related]
5. The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study.
Shin SH; Kim HJ; Hwang DW; Lee JH; Song KB; Jun E; Shim IK; Hong SM; Kim HJ; Park KM; Lee YJ; Kim SC
Oncotarget; 2017 Mar; 8(11):17945-17959. PubMed ID: 28160547
[TBL] [Abstract][Full Text] [Related]
6. A comprehensive examination of Smad4, Smad6 and Smad7 mRNA expression in pancreatic ductal adenocarcinoma.
Singh P; Wig JD; Srinivasan R; Radotra BD
Indian J Cancer; 2011; 48(2):170-4. PubMed ID: 21768661
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-301a-3p promotes pancreatic cancer progression via negative regulation of SMAD4.
Xia X; Zhang K; Cen G; Jiang T; Cao J; Huang K; Huang C; Zhao Q; Qiu Z
Oncotarget; 2015 Aug; 6(25):21046-63. PubMed ID: 26019136
[TBL] [Abstract][Full Text] [Related]
8. Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer.
Liang C; Shi S; Qin Y; Meng Q; Hua J; Hu Q; Ji S; Zhang B; Xu J; Yu XJ
Gut; 2020 May; 69(5):888-900. PubMed ID: 31611300
[TBL] [Abstract][Full Text] [Related]
9. Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma.
Hsieh YY; Liu TP; Chou CJ; Chen HY; Lee KH; Yang PM
Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31569425
[TBL] [Abstract][Full Text] [Related]
10. SMAD4 Y353C promotes the progression of PDAC.
Wang Z; Li Y; Zhan S; Zhang L; Zhang S; Tang Q; Li M; Tan Z; Liu S; Xing X
BMC Cancer; 2019 Nov; 19(1):1037. PubMed ID: 31684910
[TBL] [Abstract][Full Text] [Related]
11. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
[TBL] [Abstract][Full Text] [Related]
12. Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma.
Fan J; Yang MX; Ouyang Q; Fu D; Xu Z; Liu X; Mino-Kenudson M; Geng J; Tang F
Hum Pathol; 2016 Sep; 55():151-8. PubMed ID: 27195906
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia.
Kojima K; Vickers SM; Adsay NV; Jhala NC; Kim HG; Schoeb TR; Grizzle WE; Klug CA
Cancer Res; 2007 Sep; 67(17):8121-30. PubMed ID: 17804724
[TBL] [Abstract][Full Text] [Related]
14. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of cancer stem cell marker CD133 expression in pancreatic ductal adenocarcinoma (PDAC): a systematic review and meta-analysis.
Li X; Zhao H; Gu J; Zheng L
Int J Clin Exp Pathol; 2015; 8(10):12084-92. PubMed ID: 26722393
[TBL] [Abstract][Full Text] [Related]
16. TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status.
Liang C; Xu J; Meng Q; Zhang B; Liu J; Hua J; Zhang Y; Shi S; Yu X
Autophagy; 2020 Mar; 16(3):486-500. PubMed ID: 31177911
[TBL] [Abstract][Full Text] [Related]
17. SMAD4: a predictive marker of PDAC cell permissiveness for oncolytic infection with parvovirus H-1PV.
Dempe S; Stroh-Dege AY; Schwarz E; Rommelaere J; Dinsart C
Int J Cancer; 2010 Jun; 126(12):2914-27. PubMed ID: 19856310
[TBL] [Abstract][Full Text] [Related]
18. Pattern of Invasion in Human Pancreatic Cancer Organoids Is Associated with Loss of SMAD4 and Clinical Outcome.
Huang W; Navarro-Serer B; Jeong YJ; Chianchiano P; Xia L; Luchini C; Veronese N; Dowiak C; Ng T; Trujillo MA; Huang B; Pflüger MJ; Macgregor-Das AM; Lionheart G; Jones D; Fujikura K; Nguyen-Ngoc KV; Neumann NM; Groot VP; Hasanain A; van Oosten AF; Fischer SE; Gallinger S; Singhi AD; Zureikat AH; Brand RE; Gaida MM; Heinrich S; Burkhart RA; He J; Wolfgang CL; Goggins MG; Thompson ED; Roberts NJ; Ewald AJ; Wood LD
Cancer Res; 2020 Jul; 80(13):2804-2817. PubMed ID: 32376602
[TBL] [Abstract][Full Text] [Related]
19. Clinical Effect of Driver Mutations of
Gu Y; Ji Y; Jiang H; Qiu G
Genet Test Mol Biomarkers; 2020 Dec; 24(12):777-788. PubMed ID: 33347393
[No Abstract] [Full Text] [Related]
20. SMAD4 represses FOSL1 expression and pancreatic cancer metastatic colonization.
Dai C; Rennhack JP; Arnoff TE; Thaker M; Younger ST; Doench JG; Huang AY; Yang A; Aguirre AJ; Wang B; Mun E; O'Connell JT; Huang Y; Labella K; Talamas JA; Li J; Ilic N; Hwang J; Hong AL; Giacomelli AO; Gjoerup O; Root DE; Hahn WC
Cell Rep; 2021 Jul; 36(4):109443. PubMed ID: 34320363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]